B
코오롱생명과학
102940KOSDAQ62.0 / 100
Reference Date: 2026-10-23
Financial Score31.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Kolon Life Science operates three business segments: Chemical, SC, and Bio. The Chemical segment, focused on pharmaceutical API production, drives revenue growth due to expanding global pharmaceutical markets and increased outsourcing of raw material production. However, the Bio segment continues to report significant losses.
Number of Employees
454people
Average Salary
60.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
6.78Industry Average 15.008.0Point
Half of industry avg (excellent)
PBR
0.29Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
6.81Industry Average 8.002.5Point
Below industry avg
Debt Ratio
27.50Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲29.5% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲94.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -26.1% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (1%, downtrend)
Current 12,920Won52-week high 70,80052-week low 12,180
1-month return1.0Point
1m -8.17% (falling)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0